learn more about us

New level of
effectiveness for fungal

learn more about MYC-053

MYC-053 is a new
frontier in antifungal

learn more about us

Passionately committed to the development of innovative antifungals to treat life-threatening multi-drug resistant infections

TGV-Therapeutics is a biopharmaceutical company focused on the development of novel drugs that can address unmet clinical needs in the treatment of life-threatening systemic fungal infections.

Our lead product candidate, MYC-053, is a novel, antifungal agent that is structurally distinct from the three main classes of antifungal antibiotics.

The effectiveness of MYC-053 against the currently incurable multidrug-resistant fungal infections is attributed to its distinct chemical structure.

We developed MYC-053 as an oral drug primarily for the treatment of harmful fungal diseases in humans.

Our mission

TGV-Therapeutics is a biopharmaceutical company committed to and developing novel antifungal antibiotics that will bring therapy of invasive fungal infections to a principally new level of effectiveness.

TGV -Therapeutics’ ultimate goal is to apply the MYC-053 to some of the most deadly fungal infections — those caused by multiresistant Candida species, including Candida auris.

MYC-053 has a broad spectrum of activity covering key non-albicans Candida species, including multidrug-resistant C. glabrata and C. auris.
MYC-053 exhibits potent activity against mulridrug-resistant clinical fungal icolates
MYC-053 can be used to treat serious or life-threatening fungal infections
The science
About us
Our pipeline